Table 5 Treatment uptake in study cohorts of people who inject drugs (current and former)
Author, year | % treated (# treated/# of treatment candidates | SVR (%) (# with sustained viral response/# treated) |
|---|---|---|
Broers et al, 2005 | 61% of RNA+ (11/18) | Intent-to-treat: 56% (6/11) As-treated: 100% (3/3) |
Cournot et al, 2004 | 39% of antibody+ (58/150) | Intent-to-treat: 22% (15/68)1 |
| Â | 57% of RNA+ (58/102) | Â |
| Â | 71% of other (58/82) | Â |
Crespo et al, 2001 | 64% of antibody+ (268/416) | NA |
Gazdag et al, 2010 | 47% of RNA+ (39/83) | NA |
Guadagnino et al, 2007 | 31% of RNA+ (53/169) | Intent-to-treat: 55% (29/53) As-treated: 85% (29/34) |
Hernandez et al, 2009 | 0% of RNA+ (0/4) | NA |
Jowett et al, 2000 | 20% of antibody+ (50/253) | Intent-to-treat: 36% (18/50) |
| Â | 29% of RNA+ (50/172) | Â |
| Â | 50% of other (50/100) | Â |
Kieran et al, 2011 | 21% of RNA+ (67/327) | Intent-to-treat: 43% (29/67) |
Perez-Alvarez et al, 2012 | 56% of RNA+ (15/27) | NA |
Reiberger et al, 2011 | 32% of RNA+ (201/637) | NA |
van der Veen, 2009 | 48% of RNA+ (35/73) | NA |